Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Front Neuroinform ; 16: 924547, 2022.
Article in English | MEDLINE | ID: mdl-35898959

ABSTRACT

Early detection is crucial to control the progression of Alzheimer's disease and to postpone intellectual decline. Most current detection techniques are costly, inaccessible, or invasive. Furthermore, they require laborious analysis, what delays the start of medical treatment. To overcome this, researchers have recently investigated AD detection based on electroencephalography, a non-invasive neurophysiology technique, and machine learning algorithms. However, these approaches typically rely on manual procedures such as visual inspection, that requires additional personnel for the analysis, or on cumbersome EEG acquisition systems. In this paper, we performed a preliminary evaluation of a fully-automated approach for AD detection based on a commercial EEG acquisition system and an automated classification pipeline. For this purpose, we recorded the resting state brain activity of 26 participants from three groups: mild AD, mild cognitive impairment (MCI-non-AD), and healthy controls. First, we applied automated data-driven algorithms to reject EEG artifacts. Then, we obtained spectral, complexity, and entropy features from the preprocessed EEG segments. Finally, we assessed two binary classification problems: mild AD vs. controls, and MCI-non-AD vs. controls, through leave-one-subject-out cross-validation. The preliminary results that we obtained are comparable to the best reported in literature, what suggests that AD detection could be automatically detected through automated processing and commercial EEG systems. This is promising, since it may potentially contribute to reducing costs related to AD screening, and to shortening detection times, what may help to advance medical treatment.

2.
Comput Methods Programs Biomed ; 220: 106841, 2022 Jun.
Article in English | MEDLINE | ID: mdl-35523023

ABSTRACT

Early detection is critical to control Alzheimer's disease (AD) progression and postpone cognitive decline. Traditional medical procedures such as magnetic resonance imaging are costly, involve long waiting lists, and require complex analysis. Alternatively, for the past years, researchers have successfully evaluated AD detection approaches based on machine learning and electroencephalography (EEG). Nonetheless, these approaches frequently rely upon manual processing or involve non-portable EEG hardware. These aspects are suboptimal regarding automated diagnosis, since they require additional personnel and hinder portability. In this work, we report the preliminary evaluation of a self-driven AD multi-class discrimination approach based on a commercial EEG acquisition system using sixteen channels. For this purpose, we recorded the EEG of three groups of participants: mild AD, mild cognitive impairment (MCI) non-AD, and controls, and we implemented a self-driven analysis pipeline to discriminate the three groups. First, we applied automated artifact rejection algorithms to the EEG recordings. Then, we extracted power, entropy, and complexity features from the preprocessed epochs. Finally, we evaluated a multi-class classification problem using a multi-layer perceptron through leave-one-subject-out cross-validation. The preliminary results that we obtained are comparable to the best in literature (0.88 F1-score), what suggests that AD can potentially be detected through a self-driven approach based on commercial EEG and machine learning. We believe this work and further research could contribute to opening the door for the detection of AD in a single consultation session, therefore reducing the costs associated to AD screening and potentially advancing medical treatment.


Subject(s)
Alzheimer Disease , Cognitive Dysfunction , Wearable Electronic Devices , Alzheimer Disease/diagnostic imaging , Cognitive Dysfunction/diagnosis , Electroencephalography/methods , Humans , Machine Learning
3.
Sci Rep ; 12(1): 3563, 2022 03 03.
Article in English | MEDLINE | ID: mdl-35241761

ABSTRACT

Neurologic impairment persisting months after acute severe SARS-CoV-2 infection has been described because of several pathogenic mechanisms, including persistent systemic inflammation. The objective of this study is to analyze the selective involvement of the different cognitive domains and the existence of related biomarkers. Cross-sectional multicentric study of patients who survived severe infection with SARS-CoV-2 consecutively recruited between 90 and 120 days after hospital discharge. All patients underwent an exhaustive study of cognitive functions as well as plasma determination of pro-inflammatory, neurotrophic factors and light-chain neurofilaments. A principal component analysis extracted the main independent characteristics of the syndrome. 152 patients were recruited. The results of our study preferential involvement of episodic and working memory, executive functions, and attention and relatively less affectation of other cortical functions. In addition, anxiety and depression pictures are constant in our cohort. Several plasma chemokines concentrations were elevated compared with both, a non-SARS-Cov2 infected cohort of neurological outpatients or a control healthy general population. Severe Covid-19 patients can develop an amnesic and dysexecutive syndrome with neuropsychiatric manifestations. We do not know if the deficits detected can persist in the long term and if this can trigger or accelerate the onset of neurodegenerative diseases.


Subject(s)
COVID-19/psychology , Cognition Disorders/psychology , Mental Disorders/psychology , COVID-19/virology , Humans , SARS-CoV-2/isolation & purification , Severity of Illness Index
4.
Curr Alzheimer Res ; 17(8): 698-708, 2020.
Article in English | MEDLINE | ID: mdl-33167840

ABSTRACT

INTRODUCTION: In the absence of a gold standard for in vivo Alzheimer disease (AD) diagnosis, AD biomarkers such as cerebrospinal fluid biomarkers (CSF-B) and PET-Amyloid are considered diagnostically useful in clinical practice guidelines and have consensual appropriate use criteria (AUC). However, little evidence has been published on their utilization in the clinical setting or on approaches to mismatched results. The objective of this work was to evaluate the use of AD biomarkers in clinical practice, focusing on the implementation of PET-Amyloid in cases of inconclusive CSF-B. METHODS: This naturalistic, ambispective case series included patients fulfilling AUC for CSF-B and PET-Amyloid whose CSF-B results were non-diagnostic (target population), analyzing the diagnostic certainty, the treatment approach, and the relationship between CSF-B and PET-Amyloid results. RESULTS: Out of 2373 eligible patients, AD biomarkers were studied in 417 (17.6%), most frequently due to cognitive impairment in under 65-year-olds, using CSF-B in 311 patients and PET-Amyloid in 150. CSF-B results were non-diagnostic for 44 patients (52.3% male; aged 60.9±6.6 years), who then underwent PET-Amyloid study, which was positive in 31. A 'k' coefficient of 0.108 was obtained between CSF-B and PET-amyloid (54.5% concordance). In multivariate regression analysis, Aß42 was the only significant predictor (p= 0.018) of a positive PET-Amyloid result. In the target population, PETAmyloid increased diagnostic confidence by 53.7% (p <0.001) and modified the therapeutic approach in 36.4% of cases. CONCLUSION: These findings support the duplication of AD biomarkers and demonstrate that the implementation of PET-Amyloid provides an early and certain diagnosis to guide appropriate treatment.


Subject(s)
Alzheimer Disease/diagnosis , Amyloidogenic Proteins/cerebrospinal fluid , Aged , Alzheimer Disease/cerebrospinal fluid , Alzheimer Disease/diagnostic imaging , Amyloid beta-Peptides/cerebrospinal fluid , Amyloid beta-Peptides/metabolism , Amyloidogenic Proteins/metabolism , Biomarkers/cerebrospinal fluid , Female , Humans , Male , Middle Aged , Peptide Fragments/cerebrospinal fluid , Peptide Fragments/metabolism , Positron-Emission Tomography , Sensitivity and Specificity
5.
Alzheimer (Barc., Internet) ; (59): 6-13, ene.-abr. 2015. tab, ilus
Article in Spanish | IBECS | ID: ibc-131934

ABSTRACT

Introducción: el Fototest es un test cognitivo muy breve y aplicable a analfabetos que se ha mostrado válido y coste- efectivo en la detección del deterioro cognitivo y la demencia y en el seguimiento de estos pacientes. Las aplicaciones repetidas de un test cognitivo pueden inducir mejorías en el rendimiento debido al fenómeno «efecto de la práctica »; este efecto puede minimizarse con el uso de formas paralelas. Nuestro objetivo es evaluar la equivalencia de tres versiones paralelas del Fototest. Material y métodos: estudio transversal en una muestra de conveniencia; los sujetos se distribuyeron aleatoriamente en tres grupos a los que se aplicó respectivamente la versión original (Fototest- 1) y dos versiones paralelas (Fototest-2 y Fototest-3) del Fototest, que diferían en los objetos por denominar y recordar. Análisis estadístico: estadística descriptiva univariada y comparación entre grupos con ANOVA o χ2 según tipo de variables. Resultados: 223 sujetos (65,3 % mujeres) con una edad de 58,0 ± 16,8 (media ± DE) años, distribuidos aleatoriamente en tres grupos de 75 (Fototest-1), 76 (Fototest-2) y 72 (Fototest-3) sujetos; estos grupos no diferían entre sí en edad, sexo o nivel educativo. No hay diferencias significativas entre los grupos en las puntuaciones parciales (denominación, fluencia hombres, fluencia mujeres, recuerdo libre y recuerdo facilitado), subtotales (fluencia total, recuerdo total) y total del Fototest (Fototest-1: 37,8 ± 5,6, Fototest-2: 36,8 ± 7,5, Fototest-3: 37,4 ± 5,8; p = 0,66). Discusión: las tres versiones del Fototest son equivalentes e intercambiables, lo que puede facilitar la labor del explorador y contrarrestar el «efecto de la práctica » asociado al uso repetido (AU)


Introduction: The Phototest is a very short cognitive test that is applicable to illiterates and has proven to be valid and cost-effective for the detection of cognitive impairment and dementia and for the follow-up of these patients. Repeated applications of a cognitive test may induce improvements in performance due to «practice effects», which can be minimized by the use of parallel forms. Our objective was to evaluate the equivalence of three parallel versions of the Phototest. Material and Methods: Cross-sectional study of a convenience sample; participants were randomly distributed into three groups for the respective application of the original version of the Phototest (Phototest-1) and two parallel versions (Phototest-2 and Phototest-3), which differ in the objects to be named and recalled. Statistical analysis: univariate descriptive statistics and comparison among groups using ANOVA or the chi-square test according to the type of variable. Results: 223 participants (65.3% females) with a mean±SD of 58.0±16.8 yrs were randomly distributed among three groups of 75 (Phototest-1), 76 (Phototest-2) and 72 (Phototest-3) participants, with no significant inter-group differences in age, sex, or educational level. The groups did not significantly differ in partial Phototest scores (naming, fluency of males, fluency of females, free recall or cued recall), subtotal scores (total fluency, total recall) or total scores (Phototest-1: 37.8±5.6, Fototest-2: 36.8±7.5, Fototest-3: 37.4±5.8; p=0.66). Discussion: The three versions of Phototest are equivalent and interchangeable, which can assist the work of the examiner and counteract the 'practice effects' associated with repeated applications (AU)


Subject(s)
Humans , Male , Female , Middle Aged , Cognitive Behavioral Therapy/methods , Cognitive Dissonance , Cognitive Dysfunction/complications , Cognitive Dysfunction/diagnosis , Cognitive Dysfunction/psychology , Photograph/instrumentation , Photograph/methods , Psychological Tests/statistics & numerical data , Mental Recall/physiology , Educational Status , Cross-Sectional Studies/methods , Cross-Sectional Studies , Analysis of Variance , Reproducibility of Results
SELECTION OF CITATIONS
SEARCH DETAIL
...